Publications by authors named "Phillip A Gall"
Article Synopsis
- Understanding viral tropism for SARS-CoV-2 is crucial in preventing transmission and reducing COVID-19-related deaths.
- Current research reveals varying levels of ACE2 and TMPRSS2, key entry factors for the virus, in human head and neck tissues, with a higher affinity for the nasal cavity and trachea.
- The study also finds that smoking is linked to increased SARS-CoV-2 infection rates in the proximal airway, potentially due to lower interferon levels in smokers, contributing to their higher risk of severe COVID-19.
The larynx is an essential organ in the respiratory tract and necessary for airway protection, respiration, and phonation. Cigarette smoking is a significant risk factor associated with benign and malignant laryngeal diseases. Despite this association, the underlying mechanisms by which cigarette smoke (CS) drives disease development are not well elucidated.
View Article and Find Full Text PDFThe coronavirus SARS-CoV-2 is the causative agent of the ongoing severe acute respiratory disease pandemic COVID-19. Tissue and cellular tropism is one key to understanding the pathogenesis of SARS-CoV-2. We investigate the expression and subcellular localization of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), within the upper (nasal) and lower (pulmonary) respiratory tracts of human donors using a diverse panel of banked tissues.
View Article and Find Full Text PDFArticle Synopsis
- - The study focused on the expression and location of the SARS-CoV-2 receptor, ACE2, in the upper and lower respiratory tracts of healthy individuals.
- - Researchers found that ACE2 is present in the cilia of airway epithelial cells, suggesting this is a key entry point for the virus during respiratory transmission.
- - The investigation revealed that factors like demographics, clinical characteristics, co-morbidities, and the use of certain medications (ACE inhibitors or ARBs) do not affect ACE2 protein levels in the cilia.
Leading-Brand Advertisement of Quitting Smoking Benefits for E-Cigarettes.
Am J Public Health
November 2016
Objectives: To provide regulators and the US Food and Drug Administration with a description of cessation-themed advertising among electronic cigarette (e-cigarette) brands.
Methods: We performed a content analysis of 6 months (January through June 2015) of advertising by e-cigarette brands on their company-sponsored social media channels and blogs as well as user-generated content (testimonials) appearing within brand-sponsored Web sites. An explicit claim of cessation efficacy unambiguously states that e-cigarettes help in quitting smoking, and implicit claims use euphemisms such as "It works.